Physician profile
Amit Mann
NPI 1063605129
$6,834.86
in general payments reported to CMS, 2019-2025
18 companies · $3,801 in 2025
The $3,801 reported for 2025 was more than what 91% of Critical Care Medicine (Internal Medicine) providers received nationally (typical 2025 total: $189).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $202 · 2020: $28.33 · 2021: $59.78 · 2022: $104 · 2023: $2,375 · 2024: $265 · 2025: $3,801.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,928 · Consulting Fee: $2,108 · Travel and Lodging: $1,226 · Education: $179.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,927.50 |
| Consulting Fee | $2,108.00 |
| Travel and Lodging | $1,226.25 |
| Education | $178.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $2,794.19 | 2022-2025 | |
| Intuitive Surgical, INC. | $1,368.16 | 2023 | Da Vinci Surgical System |
| Inari Medical, INC. | $728.41 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Actelion Pharmaceuticals US, INC. | $394.32 | 2025 | Opsumit, Uptravi |
| Regeneron Healthcare Solutions, INC. | $351.04 | 2024-2025 | Dupixent |
| Glaxosmithkline, LLC. | $264.75 | 2019-2025 | Nucala, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $217.04 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $157.18 | 2021-2025 | Ofev, Jascayd |
| Abiomed | $144.74 | 2023 | Impella |
| Allergan, INC. | $134.22 | 2019 | |
| Insmed, INC. | $68.42 | 2024-2025 | Arikayce, Brinsupri |
| Baxter Healthcare | $65.80 | 2024-2025 | Hillrom - Vest System Model 105 Home Care |
| Philips North America LLC | $58.88 | 2019-2021 | |
| Invivyd INC | $20.64 | 2025 | Pemgarda |
| Inogen, INC. | $18.82 | 2025 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $18.60 | 2022 | |
| Mylan Specialty L.P. | $15.34 | 2019 | |
| Chiesi USA, INC. | $14.31 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amit Mann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.